280 related articles for article (PubMed ID: 7526527)
1. Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer.
Pollack A; Zagars GK; el-Naggar AK; Terry NH
Urology; 1994 Nov; 44(5):711-8. PubMed ID: 7526527
[TBL] [Abstract][Full Text] [Related]
2. Near-diploidy: a new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy.
Pollack A; Zagars GK; el-Naggar AK; Gauwitz MD; Terry NH
Cancer; 1994 Apr; 73(7):1895-903. PubMed ID: 7511039
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of DNA ploidy in clinically localized prostate cancer treated with radiation therapy.
Gauwitz MD; Pollack A; el-Naggar AK; Terry NH; von Eschenbach AC; Zagars GK
Int J Radiat Oncol Biol Phys; 1994 Mar; 28(4):821-8. PubMed ID: 8138434
[TBL] [Abstract][Full Text] [Related]
4. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer.
Pollack A; Zagars GK; Kavadi VS
Cancer; 1994 Jul; 74(2):670-8. PubMed ID: 7518341
[TBL] [Abstract][Full Text] [Related]
5. Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy.
Khoo VS; Pollack A; Cowen D; Joon DL; Patel N; Terry NH; Zagars GK; von Eschenbach AC; Meistrich ML; Troncoso P
Prostate; 1999 Nov; 41(3):166-72. PubMed ID: 10517874
[TBL] [Abstract][Full Text] [Related]
6. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer.
Amling CL; Lerner SE; Martin SK; Slezak JM; Blute ML; Zincke H
J Urol; 1999 Mar; 161(3):857-62; discussion 862-3. PubMed ID: 10022701
[TBL] [Abstract][Full Text] [Related]
7. Influence of DNA ploidy and adjuvant treatment on progression and survival in patients with pathologic stage T3 (PT3) prostate cancer after radical retropubic prostatectomy.
Hawkins CA; Bergstralh EJ; Lieber MM; Zincke H
Urology; 1995 Sep; 46(3):356-64. PubMed ID: 7544934
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
Zagars GK; Pollack A; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
[TBL] [Abstract][Full Text] [Related]
9. DNA ploidy and survival of patients with clinically localized prostate cancer treated without intent to cure.
Borre M; Høyer M; Nerstrøm B; Overgaard J
Prostate; 1998 Sep; 36(4):244-9. PubMed ID: 9719024
[TBL] [Abstract][Full Text] [Related]
10. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer.
Zelefsky MJ; Ben-Porat L; Scher HI; Chan HM; Fearn PA; Fuks ZY; Leibel SA; Venkatraman ES
J Clin Oncol; 2005 Feb; 23(4):826-31. PubMed ID: 15681527
[TBL] [Abstract][Full Text] [Related]
11. DNA ploidy and prostate-specific antigen as prognostic factors in clinically resectable prostate cancer.
Badalament RA; O'Toole RV; Young DC; Drago JR
Cancer; 1991 Jun; 67(12):3014-23. PubMed ID: 1710533
[TBL] [Abstract][Full Text] [Related]
12. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations.
Lee WR; Hanks GE; Hanlon A
J Clin Oncol; 1997 Jan; 15(1):230-8. PubMed ID: 8996147
[TBL] [Abstract][Full Text] [Related]
13. DNA ploidy, Gleason score, pathological stage and serum PSA levels as predictors of disease-free survival in C-D1 prostatic cancer patients submitted to radical retropubic prostatectomy.
Di Silverio F; D'Eramo G; Buscarini M; Sciarra A; Casale P; Di Nicola S; Loreto A; Seccareccia F; De Vita R
Eur Urol; 1996; 30(3):316-21. PubMed ID: 8931963
[TBL] [Abstract][Full Text] [Related]
14. DNA ploidy measured on archived pretreatment biopsy material may correlate with prostate-specific antigen recurrence after prostate brachytherapy.
Keyes M; Macaulay C; Hayes M; Korbelik J; Morris WJ; Palcic B
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):829-34. PubMed ID: 23688814
[TBL] [Abstract][Full Text] [Related]
15. Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy.
Spiess PE; Lee AK; Leibovici D; Wang X; Do KA; Pisters LL
Cancer; 2006 Jul; 107(2):275-80. PubMed ID: 16770783
[TBL] [Abstract][Full Text] [Related]
16. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome.
Zagars GK; Pollack A
Urology; 1995 Mar; 45(3):476-83. PubMed ID: 7533459
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer.
Pollack A; Zagars GK; Kopplin S
Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):13-20. PubMed ID: 7536720
[TBL] [Abstract][Full Text] [Related]
18. [PSA doubling time in prostate cancer relapsed after endocrine therapy].
Nakata S; Takahashi H; Takezawa Y; Kobayashi M; Matumoto K; Kosaku N; Kawashima K
Nihon Hinyokika Gakkai Zasshi; 2000; 91(7-8):584-8. PubMed ID: 10965743
[TBL] [Abstract][Full Text] [Related]
19. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer.
Zagars GK; Pollack A
Radiother Oncol; 1997 Sep; 44(3):213-21. PubMed ID: 9380819
[TBL] [Abstract][Full Text] [Related]
20. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy.
Zagars GK
J Urol; 1994 Nov; 152(5 Pt 2):1786-91. PubMed ID: 7523725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
